Pediatric Asthma: Pharmacotherapy. Joseph Spahn, MD Children s Hospital Colorado & University of Colorado Medical School Aurora, Colorado
|
|
- Rachel McCormick
- 5 years ago
- Views:
Transcription
1 Pediatric Asthma: Pharmacotherapy Joseph Spahn, MD Children s Hospital Colorado & University of Colorado Medical School Aurora, Colorado
2 Pediatric Asthma: Pharmacotherapy Disclosures/Conflicts of Interest: None Discussion of investigational drugs: Dupilumab in childhood asthma. Focus on: Inhaled steroids: first-line for all levels of persistent asthma Effectiveness and safety Comparative efficacy of inhaled steroid vs. leukotriene receptor antagonists Combination therapy in patients inadequately controlled on low- to moderate dose inhaled steroids What is the best add-on therapy Concerns re: safety of long-acting beta-agonists Biologic agents for use in severe asthma
3 Use of Inhaled Steroids in Children with Asthma 1. Inhaled steroids were approved for use in asthma in 1974! Yet they were reserved for those with severe asthma Theophylline was the preferred drug until the mid-1980 s 2. Inhaled steroids were not recommended for children with mild persistent asthma until the 2002 NHLBI Update on the Diagnosis & Management of Asthma. This recommendation change came from 2 studies. The CAMP study and a long-term safety study from Denmark. Both studies published in the same issue of the N Engl J Med in 2000.
4 Inhaled Glucocorticoid Therapy: Products and Doses for Children Glucocorticoid Low daily dose Medium daily dose Beclomethasone (Qvar ) MDI: 40 or 80 µg/puff (Approved for children 5 y.o.) Budesonide (Pulmicort Flexhaler ) DPI: 90, 180 µg/puff (Approved for children 6 y.o.) Budesonide suspension for nebulization (Pulmicort Respules ); 0.25 mg, 0.5 mg, 1.0 mg/2 ml (Approved for children 1 to 8 y.o.) Ciclesonide (Alvesco ) MDI: 80, 160 µg/puff (Approved for children 12 y.o.) Flunisolide (Aerospan ) MDI: 80 µg/puff (Approved for children 6 y.o.) Fluticasone propionate (Flovent, Flovent Diskus ) MDI: 44, 110, 220 mcg DPI: 50, 100, 250 mcg (44 and 50 mcg approved for children 4 y.o.) Fluticasone furoate (Arnuity Ellipta ) DPI: 100, 200 mcg (Approved for children 12 y.o.) Mometasone Furoate (Asmanex, Asmanex Twisthaler ) MDI: 100, 200 mcg DPI: 110, 220 mcg (Approved for children 4 y.o.) High daily dose mcg mcg >320 mcg 200 mcg mcg >400 mcg 0.5 mg 1.0 mg 2.0 mg 80 mcg mcg 160 mcg 80 mcg mcg 160 mcg mcg mcg mcg 200 to 500 mcg >440 mcg >500 mcg 100 mcg mcg 200 mcg 110 mcg 100 mcg 110 mcg (100 mcg 110 mcg 100 mcg
5 The Efficacy of Inhaled Glucocorticoids in Asthma The Most Extensively Studied & Most Effective Class of Controllers Agents! 1. Decrease asthma symptoms 2. Improve lung function 3. Reduce in asthma morbidity/mortality less need for oral glucocorticoids protection against hospitalization protection against asthma death 4. Reduce bronchial hyperresponsiveness
6 Percentage Placebo History: Dutch Chronic Non-specific Respiratory Disease Study Group 116 children with moderate asthma (mean FEV 1 77% of predicted) received budesonide 200 mcg or placebo three times/day for 2 to 3 yrs. Budesonide 0 Withdrawals Exacerbations Change in FEV 1 (%) 10 Van Essen-Zandvleit et al., Am Rev Respir Dis 1992;146: % -6 Budesonide Placebo PD 20 µg 0 Budesonide Placebo Months 20
7 Childhood Asthma Management Program (CAMP) budesonide 200 mcg BID (n=311) 1041 children 5-12 y.o. nedocromil 8 mcg BID (n=312) placebo (n=418) 5 years to 12 year old children with mild to moderate asthma based on symptom frequency and need for controller therapy were studied. Baseline FEV 1 94%, post-albuterol FEV 1 103% of predicted, moderate AW reactivity (PC 20 1 mg/ml). Primary endpoint: Change in post-albuterol FEV 1 hildhood Asthma Management Program Research Group. N Engl J Med 2000;343:
8 Efficacy of Long-Term Inhaled Steroid Therapy in Children with Asthma Budesonide had no effect on post-albuterol FEV 1 but... - Reduction in level of AHR ( airways twitchiness ) - 43% Fewer hospitalizations - 45% Fewer urgent care visits - 43% Fewer courses of prednisone - Less need for rescue β-agonist - Fewer number of days requiring supplemental inhaled GC therapy 6.6% of budesonide treated patients vs.17.1% of nedocromil and 18.7% of placebo treated patients *CAMP Research Study group. N Engl J Med 2000;343:
9 Safety of Long-Term Budesonide Therapy Growth: - Mean increase in height of budesonide 1.1 cm less than placebo group which occurred in the first year BUD 22.7 cm, NED 23.7 cm, Placebo 23.8 cm - Projected final height for each group was identical* cm for budesonide,,nedocromil, & placebo. Bone Mineral Density (BMD): - Lumbar BMD performed yearly: no difference between groups at any time during the study. *Follow-up growth study found budesonide-treated patients to be 1 cm shorter vs. placebo-treated patients as young adults. CAMP Research Group. N Engl J Med 2000;343: *Kelly W et al. N Engl J Med 2012;
10 Prevention of Early Asthma In Kids (PEAK): Study Design Screening/ Eligibility Run-in Treatment Observation 1 month 1 month Years 1 & 2 Year 3 Randomize Interim Efficacy Primary Outcome 280 children (2 to 3 y.o.) at risk for asthma (+mapi) randomized to receive fluticasone propionate (44µg/puff) or placebo (2 puffs MDI BID) for 2 years with a 3 rd observation year. Sought to determine if early intervention would prevent the development of asthma.
11 Hypothetical Representation of the Natural History of Asthma Inception Early Administration of Inhaled Steroid Rx Chronic Asthma No Asthma Asthma Initial Phase Protection Asthma, Not Chronic Exacerbations No Asthma Modified API: Must have > 4 wheezing episodes in the past year plus One major criteria Two minor criteria or Parent with asthma Food sensitivity Atopic dermatitis Eosinophilia ( 4%) Allergen sensitivity Wheezing without infection
12 Outcomes During Observation Phase (Year 3) Primary Outcome: Episode-free days during the observation-year (off controller for 1 yr) No differences between groups seen for: - Number of exacerbations requiring prednisone bursts - Unscheduled physician visits/ hospitalizations - Bronchodilator use - Montelukast use - Lung function (respiratory system impedance) No differences in adherence, drop-outs, treatment failures or serious adverse events between groups. Guilbert et al., N Engl J Med 2006;354:
13 Was Any Effect Seen During Treatment?
14 PEAK Study: Outcomes During Treatment Phase (Years 1 & 2) Fluticasone superior to placebo in: - Number of episode-free days - Number of acute exacerbations - Need for supplemental controller medications - Time to addition of supplementary asthma controller medications - Improved lung function (respiratory reactance at 5 hz) Fluticasone was associated with modest growth impairment at end of treatment. - Average height percentile for fluticasone 51.5% - Average height percentile for placebo 56.4 % Guilbert et al., N Engl J Med 2006;354:
15 Inhaled Steroids vs. Leukotriene Receptor Antagonists as Single Agent Controller Medications: What s Best?..
16 Characterization of Within-Subject Responses to Fluticasone & Montelukast in Childhood Asthma 44 Participants Randomized Period 1 8 weeks Period 2 8 weeks Treatment Failures Sequence 1 N=73 LTRA 68 completed Period 1 5 treatment failures LTRA 62 completed Period 2 5 treatment failures LTRA *10 treatment failures Sequence 2 N=71 ICS 68 completed Period 1 0 treatment failures ICS 68 completed Period 2 5 treatment failures ICS 2 treatment failures Total 136 completed Period 1 8 dropouts 5 treatment failures 127 completed Period 2 9 dropouts 5 treatment failures 12 total treatment failures
17 Characterization of Within-Subject Responses to Fluticasone & Montelukast in Childhood Asthma 144 children (6-17 y.o.) with mild to moderate asthma enrolled in a 16 wk cross-over study of fluticasone 100 mcg bid and montelukast. Sought to determine a phenotype for response. A positive response was considered an increase in FEV 1 7.5% Baseline values: FEV 1 96% FeNO 27 ppb PC mg/ml. Effect Noted for both medications 17% Effect seen only with Fluticasone: 23% Effect seen only with Montelukast: 5% No Effect with either Medication: 55% Adapted from: Szefler et al., J Allergy Clin Immunol 2005;115:
18 Many More Children had a Favorable Response to Fluticasone & had Far Fewer Treatment Failures Compared to Those Treated with Montelukast Treatment Failures (n) *p=0.019 Participants Better Response to Fluticasone (n=75) 2 Better Response to Montelukast (n=24) 0 Fluticasone Montelukast Szefler SJ, JACI 2005;115: Difference in FEV 1 Response, % of baseline (Fluticasone-Montelukast) 45
19 Fluticasone was associated >2 times the number of ACDs per week vs. Montelukast A 1 day increase in asthma control days (ACD) per week was considered a clinically significant improvement. 30% had a better response while on montelukast therapy 70% had a better response while on fluticasone therapy. Zeiger et al., J Allergy Clin Immunol 2006;117: Participants Better Response to Montelukast (n=15) Better Response to Fluticasone (n=36) Difference in ACDs per wk FP-Mt
20 Predictors of Response Baseline Characteristic ( %) Fluticasone Propionate Montelukast Pre-bronchodilator FEV 1 % predicted <90% (40%) ** 4.2 Pre-bronchodilator FEV 1 /FVC <80% ( 40%) ** 4.3 * 2.4 Methacholine PC 20 1 mg/ml (44%) Exhaled Nitric Oxide >25 ppb (55%) Circulating Eosinophil Count >350 cells/mm 3 (41%) Serum Eosinophil cationic protein >15 ng/ml (54%) ** * * ** Serum IgE >200 ku/ml (44%) ** 2.9 Urinary Leukotriene E4 >100 pg/ml (50%) * 3.2 Age <10 yrs (67%) * 2.5 **p<0.01 *p< Odds Ratio Odds Ratio Szefler et al., J Allergy Clin Immunol 2005;115:
21 Montelukast is Effective in Preschool-Aged Children with Viral-Induced Wheeze 549 children 2 to 5 y.o. with intermittent asthma received placebo or montelukast x 1yr. Montelukast vs. Placebo Exacerbations (episodes) GC courses Inhaled GCs Oral GCs Montelukast (n=265) 1.60 ( ) 1.19 (0.94, 1.51) 0.66 (0.46, 0.94) 0.53 (0.40, 0.70) Placebo (n=257) 2.34 ( ) 1.74 (1.39, 2.18) 1.10 (0.83, 1.45) 0.64 (0.47, 0.88) Bisgaard et al., Am J Respir Crit Care Med 2005;171: Relative Rate 0.68 (0.56, 0.83) 0.68 (0.49, 0.95) 0.60 ( ) 0.82 (0.54, 1.25) Rate Reduction 31.9% 31.6% 39.8% 17.5% p value <
22 Time to First Exacerbation and Seasonal Variability in Exacerbations Proportion Surviving Without an Exacerbation Episode Placebo Montelukast Percentage of Patients with an Exacerbation Episode Winter Spring Summer Autumn log-rank test: p= Time in Months Bisgaard et al., Am J Respir Crit Care Med 2005;171: Placebo Montelukast January April July October Month January
23 Summary: Inhaled Steroids Remain the most effective class of agents to treat asthma. Inhaled steroids more effective than leukotriene modifying agents in: - In atopic children of all ages - Improving baseline lung function (10-15% gain vs %) - Reducing symptoms - Reducing exacerbations Leukotriene modifying agents - Considered alternative agents to inhaled steroids - Are as effective as inhaled steroids in non-atopic viral-induced wheezers and non-atopic grade school-aged asthmatics
24 Combination Therapy for Moderate Persistent Asthma or for Asthmatics Sub-optimally Controlled on Low Dose Inhaled Steroid therapy 2002 Update to the NHLBI Asthma guidelines recommended combination inhaled steroid plus long-acting beta-agonist (LABA) therapy. The recommendations changed when the 2007 NHLBI Asthma guidelines were released due to concerns about the safety of LABA therapy treatment guidelines for 5 to12 y.o. children- 4 choices: (1) 2x inhaled steroid; (2) 1x inhaled steroid plus LTRA; (3) 1x inhaled steroid plus LABA; (4) 1x inhaled steroid plus theophylline
25 BADGER Protocol: Overview In children not satisfactorily controlled on low dose ICS therapy, what is the next best treatment approach? Increase the inhaled steroid dose? Add a LABA? Add a LTRA? Double-blind, 3 way cross-over, 3 Treatment Periods with treatment 6 Sequences Run-in period on 1x ICS to demonstrate lack of control Run-in Period 2-8 weeks Period 1 Period 2 Period 3 2.5x ICS or 1 x ICS + LABA or 1 x ICS + LTRA 2x ICS or 1x ICS + LABA or 1 x ICS + LTRA 2x ICS or 1x ICS + LABA or 1 x ICS + LTRA 16 weeks 16 weeks 16 weeks Randomization Lemanske et al., N Engl J Med 2010;362:975-85
26 Results: Differential Response A Differential response occurred in 161/165 participants (98%); p< Meaning that all patients had a favorable response to step-up therapy. Was one step-up therapy found to be more effective than the other step-up therapies? Lemanske et et al., al., N Engl N Engl J Med J Med 2010;362: ;362:975-85
27 Primary Outcome: Probability of BEST Response Based on Composite Score* LABA step-up was >1.5 times more likely to produce the best response. LABA 2.5 x igc LTRA *Composite score: 1 st exacerbations 2 nd asthma control days LABA 1.7 times better (95% CI ; p=0.002) 1.6 LABA times better (95% CI ; p=0.004) Probability of Best Response 3 rd FEV 1 emanske et al., N Engl J Med 2010;362:975-85
28 LABA Step-up was most effective in reducing exacerbations and treatment failures Type of Exacerbation Number of Treatment Failures (TF) Number of TF s due to Hospitalization for Asthma Number of TF s due to 2 nd Prednisone Burst Number of Prednisone Bursts LABA Step-up ICS Step-up LTRA Step-up Total Lemanske et et al., al., N N Engl Engl J Med J Med 2010;362:975-85
29 SMART Study
30 SMART Study Design 28-week, multicenter, RZ, DB, PC, observational Target enrollment: ~60,000 patients. Only 26,000 enrolled. Included patients >12 years with asthma currently using a prescription asthma medication (inhaled steroid use not an entry requirement) Salmeterol MDI 42 mcg BID + Usual Care (n=13,176) No inhaled long-acting beta 2 -agonist 12 years of age R 28-week treatment period Phone contact every 4 weeks Placebo MDI BID + Usual Care (n=13,179) Single Clinic Visit Nelson HS et al. Chest. 2006;129: Nelson HS et al. Chest. 2006;129: week supply of study medication provided
31 Salmeterol was associated with increased risk of death vs. placebo b-agonists, (13 vs. 3). bthere 2 ADR 9 polymorphisms deaths with salmeterol and vs. 0 deaths asthma: with placebo part therapy 2- the in patients SMART not Study treated with inhaled steroid therapy. White Black Inhaled steroids at baseline (%) ER visit past 12 months hospitalization past 12 months intubation for asthma lifetime (%) 4 8 Number of deaths (%) 6 (46) 7 (54) Effect of inhaled steroid on risk of death Inhaled steroid at randomization Salmeterol Placebo Yes 4 3 No 9 0 Nelson et al., Chest 2006;129:15-26.
32 FDA Black Box LABA warning Monotherapy with LABA in asthma is contraindicated LABAs should not be used in patients whose asthma is adequately controlled on low or medium dose inhaled GCs. LABAs should only be used as additional therapy for patients with asthma who are currently taking but are not adequately controlled on a long-term asthma control medication, such as an inhaled corticosteroid. Once asthma control is achieved and maintained, patients should be assessed at regular intervals and step down therapy should begin (e.g., discontinue LABA). Pediatric and adolescent patients who require the addition of a LABA to an inhaled corticosteroid should use a combination product containing both an inhaled corticosteroid and a LABA, to ensure adherence with both medications. FDA Drug Safety Communication June 2, 2010
33 Serious Asthma Events with Fluticasone Plus Salmeterol versus Fluticasone Alone: (VESTRI Study) 2008 FDA meta-analysis showed an increased risk of asthma-related death, intubation or hospitalization in patients on LABA vs. those not on a LABA. Another meta-analysis showed an increased risk even when used with igc in a separate inhaler than salmeterol. Safety of LABA in children is limited. The FDA metaanalysis found an increased risk of hospitalization which was mitigated when used concomitantly with igc. To address these questions, the FDA mandated GSK to perform a large safety trial. Stemple DA et al., N Engl J Med 2016;365:840-9
34 VESTRI Study To determine if fluticasone/salmeterol was non-inferior to fluticasone alone regarding risk of a serious asthmarelated event: death, intubation or hospitalization. International trial: Over 6,000 children 4 to 11 y.o. enrolled from 11/2011 to 11/2015. Randomized 1:1 on basis pre-trial medications, cact, & exacerbation history to receive either fluticasone or fluticasone/salmeterol 100 or 250 µg bid for 26 weeks. If resulting upper CI for hazard ratio for time to first serious asthma-related event (fluticasone or fluticasone/salmeterol) was <2.675, non-inferiority was demonstrated. Stemple DA et al., N Engl J Med 2016;365:840-9
35 Serious Asthma Exacerbations: Fluticasone Plus Salmeterol versus Fluticasone Alone Adherence 94% Safety Primary: - No deaths, No intubations - Hospitalizations: 27 FP/Salm and 21 FP alone. Risk for a serious asthma-related event was 1.28 for fluticasone/salmeterol vs. fluticasone. As the HR was <2.675, non-inferiority was demonstrated. Safety 2 o : 34 (1.1%) of fluticasone/salmeterol vs. 35 fluticasone treated (1.1%) patients withdrew 2 o asthma exacerbation. Stemple DA et al., N Engl J Med 2016;365:840-9
36 Efficacy of Fluticasone Plus Salmeterol 8.5% of FP/Salm vs. 10% of FP treated children had 1 severe exacerbation (HR to event 0.86). Among blacks: 6.7% FP/Salm vs. 8.4% FP (HR 0.80). Subgroups. versus Fluticasone Alone #1. Controlled on FP/Salm who remained on FP/Salm had fewer severe exacerbations vs. those whose LABA withdrawn. #2. Uncontrolled on low dose igc had fewer exacerbations when treated with FP/Salm vs. those whose igc increased. #3. Uncontrolled asthma on dose mid-fp alone. Addition of LABA to FP 250 µg resulted in fewer exacerbations. #4. Controlled on FP alone. More exacerbations when LABA added vs. FP alone 12.5% vs FP/Salm superior to FP alone in 3 of 4 subgroups. Findings contradict FDA warning stating that LABA should be discontinued once a patient s asthma is controlled on combination therapy.
37 Summary: Combination Inhaled Steroid LABA Therapy The most effective treatment for patients with moderate to severe asthma in both adults and children. They are not associated with increased risk for severe asthma attacks, or deaths from acute asthma. All 3 companies that manufacture combination products have shown similar safety results in >25,000 adults and >6,000 children. Blacks are not at increased risk of having a severe asthma attack while on combination therapy. What will happen to the Black-Box warning?
38 Biologic Agents to Treat Severe Asthma Omalizumab - Anti-IgE antibody. Available for >10 years in adults with allergic asthma, recently approved for use in children. Mepolizumab - Anti-IL-5 antibody. Available since 2016 for severe eosinophilic asthmatics 12 years old. Dupilumab - IL-4 Receptor α antibody (blocks IL-4 and IL-13) - Approved for use in adults with severe atopic dermatitis. - Undergoing Phase 3 studies in adults and children with severe asthma.
39 Omalizumab in Severe Allergic Asthma 850 patients years old with inadequately controlled asthma on high dose inhaled GC plus LABA were treated with omalizumab or placebo for 48 wks. 1 o endpoint: rate of exacerbations. 2 o endpoints: number of albuterol puffs/d, asthma symptoms score, AQLQ. Characteris*cs Omalizumab Placebo Age (yrs) Male (%) Asthma Dura;on (yr) BMI (kg/m 2 ) Serum IgE (IU/ml) FeNO (ppb) FEV 1 (% pred) Puffs rescue albuterol/d prednisone past yr Hanania et al., Ann Int Med 2011;154: Participants Without Protocol-Defined Asthma Exacerbation (%) Placebo (n=421) Omalizumab (n=427) Time Since Day 0, week
40 Omalizumab in Severe Allergic Asthma Mean Puffs of Rescue Medication Per Day Mean FeNO (ppb) Omalizumab Placebo 0.27 puff/d reduction in albuterol Omalizumab Weeks Time, week Placebo Weeks Hanania et al., Ann Int Med 2011;154: ppb reduction Not all patients respond to omalizumab. Baseline TH 2 biomarkers (FeNO, circulating eosinophils, serum periostin) were measured to determine if they could predict response. Divided into biomarker high or low groups based whether values above or below the median. Exacerbations were significantly lower in the high vs. low biomarker groups, with the greatest reduction in high FeNO group (53% reduction) vs. 32% reduction high eosinophil group and 30% reduction high periostin group. In patients in the low biomarker group, omalizumab was no more effective than placebo in reducing exacerbations. Hanania et al. Am J Respir Crit Care Med 2013;187: Fall Omalizumab vs. igc boost in inner city asthmatic children found omalizumab to be effective in reducing fall exacerbations in children with 1 exacerbation during the run-in period. Those who exacerbated had elevated FeNO levels at baseline. Teach et al. JACI 2015;136:
41 Mepolizumab For Severe Eosinophilic Asthma (DREAM): A Multicentre, Double- Blind, Placebo-Controlled Study Mepolizumab is an anti-il-5 antibody. IL-5 is the pivotal cytokine involved in eosinophil survival and activation. Eosinophils are thought to play an important role in asthma pathogenesis. 13-month study of mepolizumab in 621 severe asthmatics with frequent exacerbations and eosinophilic inflammation inadequately controlled on high-dose inhaled glucocorticoid therapy. Primary efficacy outcome: Asthma exacerbations (prednisone course, admission, or ED visit). Patients had to have evidence for eosinophilic inflammation: - 1. Sputum eosinophil 3% - 2. FeNO 50 ppb - 3. Circulating eosinophil count 300 cells/ml Pavord et al., Lancet 2012;380:
42 Baseline Characteristics Characteristic Placebo (n=155) 75 mg IV Mep 250 mg IV Mepo 750 mg IV Mepo Age (years) Asthma duration (y) Sex (female %) Atopy (%) /Nasal Polyps (%) 52 /10 51 /7 50 /14 49 /8 Sputum EOS (%) FeNO (ppb) FEV 1 (% predicted) FEV 1 reversibility LABA use (%) Severe exacerbations past yr (n) Severe asthma (<10%), several phenotypes have been identified. Severe asthma is: often adult onset, have female predominance, is less likely to be atopic, and more likely to have irreversible airflow limitation. The cohort studied consisted of adult onset asthmatics. Disease onset 33 years. 50% were atopic, & 10% had nasal polyps. Pavord et al., Lancet 2012;380:
43 Mepolizumab Resulted in a Significant Reduction in Asthma Exacerbations and.. *Total number of clinically significant exacerbations *No clear dose response was noted suggesting the lowest study dose was at the peak of the dose response curve Placebo 75 mg mepolizumab 250 mg mepolizumab 750 mg mepolizumab % -48% -52% Time from start of treatment (mo) Proportion of patients Placebo 75 mg mepolizumab 250 mg mepolizumab 750 mg mepolizumab Number of exacerbations Exacerbations Requiring Hospital Admission: Placebo: 27; 75 mg: 15; 250 mg: 17; 750 mg: 10 Pavord et al., Lancet 2012;380:
44 .And Inhibiting Eosinophils, But it Had No Effect on FEV 1, Quality of Life, Symptom Scores. Ratio of geometric mean blood eosinophil count Mean change in asthma QOL questionnaire score placebo 75 mg 250 mg 750 mg Mean change in prebronchodilator FEV 1 (ml) placebo 75 mg 250 mg 750 mg Time (weeks) Time (weeks) Pavord et al., Lancet 2012;380:
45 Efficacy Associated with Increasing Eosinophil Counts & With Number Of Exacerbations In the Previous Year A multivariate analysis identified 2 variables associated with mepolizumab efficacy: Baseline eosinophil count Exacerbation frequency in the past year. FeNO, IgE concentration and atopic status at baseline were not associated with its effectiveness. effectiveness. FeNO levels were not affected by mepolizumab therapy. Thus eosinophils, & not FeNO, predict response and are significantly reduced during mepolizumab therapy. Traditional markers of asthma such as FEV 1 and beta-agonist response were not associated with mepolizumab effectiveness. Pavord et al., Lancet 2012;380: Online supplementary material.
46 Dupilumab (Fully Humanized Monoclonal Antibody to the α-subunit of the IL-4 Receptor) in Persistent Asthma with Elevated Eosinophil Levels 104 moderate/severe eosinophilic asthmatics [circulating ( 300 cells/µl) or sputum eosinophils ( 3%)] on igc/laba therapy received dupilumab (300 mg) or placebo SQ weekly for 12 weeks. LABA discontinued at week 4, igc tapered/discontinued during weeks 6 through 9. 1 o outcome: Reduction in asthma exacerbations Screening/ Run-In Period Intervention Period ~65 patients: dupilumab, 300 mg, subcutaneously, weekly ~65 patients: placebo, subcutaneously, weekly After Intervention Period Randomization Day 29 wk 4 Day 43 wk 6 Day 50 wk 7 Day 57 wk 8 Day 64 wk 9 Day 71 wk 10 Day 78 wk 11 Day 85 wk 12 Day 127 wk 18 Day 141 wk 20 Baseline therapy Stable phase Long-acting β-agonist Inhaled Steroid Baseline therapy Withdrawal phase Dupilumab Monotherapy Wenzel S et al. N Engl J Med 2013;368:
47 Dupilumab resulted in significant reductions in exacerbations, improved lung function, & reduced symptoms vs. placebo Characteristic Placebo n=52 Age Male gender % Asthma duration (yr) # exacerbations past year Eosinophils (cells/ml) FEV 1 (% predicted) FeNO (ppb) IgE (IU/ml) Eotaxin (pg/ml) Dupilumab n=52 enzel S et al. N Engl J Med 2013;368: % with an Exacerbation % Placebo 87% reduction P< % Dupilumab Primary Outcome: Acute Exacerbations FEV 1 (% predicted) Stable on therapy LABA Withdrawal Dupilumab Placebo igc taper Dupilumab or placebo mono-therapy Weeks
48 Dupilumab Therapy Resulted in Significant Reductions in FeNO Levels, and Need for Rescue Albuterol Mean FeNO (ppb) Mean # of albuterol inhalations/d for symptom relief Mean ± SE 50 Placebo Dupilumab LABA Withdrawn igc Therapy Withdrawal No Controller Therapy Mean ± SE Placebo Dupilumab LABA Withdrawn igc Therapy Withdrawal No Controller Therapy Week 8 12 Although eosinophilia was an entry requirement, dupilumab therapy had no effect on circulating eosinophils. enzel S et al. N Engl J Med 2013;368: Online Supplementary Data Week
49 Dupilumab Efficacy & Safety: A Randomized DB, PC Pivotal Phase 2b Dose-Ranging Trial Larger study: 769 adult asthmatics on medium-to-high dose ICS/LABA therapy received subcutaneous dupilumab 200 or 300 mg q 2 to 4 week or placebo for 24 wks. Primary endpoint: Change in FEV 1 at 12 wks. Dupilumab resulted in significant improvements in FEV1, reductions in exacerbations and symptoms and improved quality of life measures/ - The effect was best with 300 mg administered q 2wks - Effect noted independent of eosinophilia, although those with eosinophils >300/µl had a greater effect. Dupilumab resulted in a rapid & significant reduction in FeNO but had no effect on eosinophils. Wenzel S et al. Lancet 2016;388;31-44.
50 Dupilumab Efficacy & Safety In Adults With Uncontrolled Asthma Despite Medium/High Dose ICS Plus LABA: Conclusions. Dupilumab is effective in 2 other atopic conditions: eczema and chronic rhinosinusitis with polyposis. Inhibition of both IL-4 and IL-13 may be an effective strategy in conditions driven by type 2 inflammation. Additionally multiple co-morbid conditions (AD, AR, sinusitis with polyposis) often exist in the same patient reflecting a systemic condition and by blocking IL-4 and IL-13 might allow a systemic solution. Inhibition of IL-4 & -13 appears to be crucial in improving lung function, reducing exacerbations, and QOL in patients with uncontrolled asthma on combination ICS/LABA therapy. Dupilumab resulted in a rapid and sustained reduction in FeNOshowing suppression of type 2 inflammation beyond which is available with combination therapy. Wenzel S et al. Lancet 2016;388;31-44.
51 Role of IL5, IL-4 & IL-13 in Asthma pathogenesis Spahn JD et al. J Allergy Clin Immunol 2016;138;
Controversial Issues in the Management of Childhood Asthma: Insights from NIH Asthma Network Studies
Controversial Issues in the Management of Childhood Asthma: Insights from NIH Asthma Network Studies Stanley J. Szefler, MD Helen Wohlberg and Herman Lambert Chair in Pharmacokinetics, Head, Pediatric
More informationDo We Need Biologics in Pediatric Asthma Management?
Do We Need Biologics in Pediatric Asthma Management? Ting Fan LEUNG, MBChB, MD, FRCPCH, FAAAAI Professor and Chairman Department of Paediatrics The Chinese University of Hong Kong Asthma and Allergy by
More informationUsing Patient Characteristics to Individualize and Improve Asthma Care
Using Patient Characteristics to Individualize and Improve Asthma Care Leonard B. Bacharier, M.D. Associate Professor of Pediatrics Clinical Director, Division of Allergy, Immunology, & Pulmonary Medicine
More informationCynthia S. Kelly, M.D. Professor of Pediatrics Eastern Virginia Medical School Division Director Allergy Children s Hospital of The King s Daughters
Cynthia S. Kelly, M.D. Professor of Pediatrics Eastern Virginia Medical School Division Director Allergy Children s Hospital of The King s Daughters Disclosures Speakers bureau of Novartis and Genentech
More informationAsthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationNucala (mepolizumab injection for subcutaneous use)
Nucala (mepolizumab injection for subcutaneous use) Policy Number: 5.01.612 Last Review: 01/2018 Origination: 02/2016 Next Review: 02/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will
More informationSearching for Targets to Control Asthma
Searching for Targets to Control Asthma Timothy Craig Distinguished Educator Professor Medicine and Pediatrics Penn State University Hershey, PA, USA Inflammation and Remodeling in Asthma The most important
More information12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationPredicting, Preventing and Managing Asthma Exacerbations. Heather Zar Department of Paediatrics & Child Health University of Cape Town South Africa
Predicting, Preventing and Managing Asthma Exacerbations Heather Zar Department of Paediatrics & Child Health University of Cape Town South Africa Asthma exacerbations Predicting exacerbation recognising
More informationBiologics in asthma Are we turning the corner? Roland Buhl Pulmonary Department Mainz University Hospital
Biologics in asthma Are we turning the corner? Roland Buhl Pulmonary Department Mainz University Hospital Biologics in asthma - are we turning the corner? Allergic asthma anti - IgE Allergic airway inflammation
More informationAlberta Childhood Asthma Pathway for Primary Care
Asthma Diagnosis Box 1 Diagnosis: Based on symptom pattern, careful and thorough history of symptoms (wheeze, cough, night waking and activity limitations), and assessment of family history of asthma and
More informationNew Therapies for Asthma
New Therapies for Asthma Tracy Bridges, MD Speaker Disclosure: Dr. Bridges participates in speaker bureaus for Teva, Genetech & Astra Zeneca. Objectives: Discuss the use of LAMA s for Asthma Detail the
More informationCinqair (reslizumab injection for intravenous use)
Cinqair (reslizumab injection for intravenous use) Policy Number: 5.02.522 Last Review: 04/2018 Origination: 04/2016 Next Review: 04/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will
More informationBiologic Therapy in the Management of Asthma. Nabeel Farooqui, MD
Biologic Therapy in the Management of Asthma Nabeel Farooqui, MD None Disclosures Objectives Define severe asthma phenotypes and endotypes Describe the role of biologics in asthma management Review pivotal
More informationDistinguishing Type-2 Asthma
UPDATE ON ASTHMA THERAPY: MATCHING PHENOTYPE TO TREATMENT Sally E. Wenzel, MD Professor of Medicine University of Pittsburgh Asthma Institute@UPMC Subsection Chief of Allergy 1234567 891234 567891 2345678
More informationLearning the Asthma Guidelines by Case Studies
Learning the Asthma Guidelines by Case Studies Timothy Craig, DO Professor of Medicine and Pediatrics Distinguished Educator Penn State University Hershey Medical Center Objectives 1. Learn the Asthma
More informationMeeting the Challenges of Asthma
Presenter Disclosure Information 11:05 11:45am Meeting the Challenge of Asthma SPEAKER Christopher Fanta, MD The following relationships exist related to this presentation: Christopher Fanta, MD: No financial
More informationGlobal Initiative for Asthma (GINA) What s new in GINA 2016?
Global Initiative for Asthma (GINA) What s new in GINA 2016? GINA Global Strategy for Asthma Management and Prevention GINA: A Brief History Established in 1993 Collaboration between NHLBI and WHO Multiple
More informationAsthma Therapy 2017 JOSHUA S. JACOBS, M.D.
Asthma Therapy 2017 JOSHUA S. JACOBS, M.D. BACKGROUND-PREVALENCE Asthma is one of the most common chronic diseases worldwide with an estimated 300 million affected individuals Prevalence is increasing
More informationManagement of asthma in preschool children with inhaled corticosteroids and leukotriene receptor antagonists Leonard B. Bacharier
Management of asthma in preschool children with inhaled corticosteroids and leukotriene receptor antagonists Leonard B. Bacharier Department of Pediatrics, Division of Allergy and Pulmonary Medicine, Washington
More informationQ: Should patients with mild asthma
1-MINUTE CONSULT CME CREDIT EDUCATIONAL OBJECTIVE: Readers will consider prescribing inhaled corticosteroids to their patients who have mild persistent asthma brief answers to specific clinical questions
More informationClinical Implications of Asthma Phenotypes. Michael Schatz, MD, MS Department of Allergy
Clinical Implications of Asthma Phenotypes Michael Schatz, MD, MS Department of Allergy Definition of Phenotype The observable properties of an organism that are produced by the interaction of the genotype
More informationIdentifying Biologic Targets to Attenuate or Eliminate Asthma Exacerbations
Identifying Biologic Targets to Attenuate or Eliminate Exacerbations exacerbations are a major cause of disease morbidity and costs. For both children and adults, viral respiratory infections are the major
More informationAsthma and Its Many Unmet Needs: Directions for Novel Therapeutic Approaches
Asthma and Its Many Unmet Needs: Directions for Novel Therapeutic Approaches William W. Busse,, M.D. University of Wisconsin School of Medicine and Public Health Madison, WI, USA Disclosure Slide Employment
More informationDisclosures. Learning Objective. Biological therapies. Biologics with action against 11/30/2011. Biologic Asthma Therapies and Individualized Medicine
Biologic Asthma Therapies and Individualized Medicine Mark S. Dykewicz, MD Director, Allergy & Immunology Fellowship Program Director Wake Forest University School of Medicine Winston-Salem, North Carolina
More informationOmalizumab (Xolair ) ( Genentech, Inc., Novartis Pharmaceuticals Corp.) September Indication
( Genentech, Inc., Novartis Pharmaceuticals Corp.) September 2003 Indication The FDA recently approved Omalizumab on June 20, 2003 for adults and adolescents (12 years of age and above) with moderate to
More informationDual-Controller Asthma Therapy: Rationale and Clinical Benefits
B/1 Dual-Controller Asthma Therapy: Rationale and Clinical Benefits MODULE B The 1997 National Heart, Lung, and Blood Institute (NHLBI) Expert Panel guidelines on asthma management recommend a 4-step approach
More informationAsthma Update I have no professional or personal financial conflicts of interest to disclose.
Asthma Update 2018 Disclosures Jennifer W. McCallister, MD, FACP, FCCP Associate Professor Division of Pulmonary, Critical Care, and Sleep Medicine The Ohio State University Wexner Medical Center I have
More informationAsthma Update Jennifer W. McCallister, MD, FACP, FCCP
Asthma Update 2018 Jennifer W. McCallister, MD, FACP, FCCP Associate Professor Division of Pulmonary, Critical Care, and Sleep Medicine The Ohio State University Wexner Medical Center Disclosures I have
More informationDrug Class Monograph
Drug Class Monograph Class: Inhaled Corticosteroids Drugs: Aerospan (flunisolide), Advair Diskus, Advair HFA (fluticasone/salmeterol), Alvesco (ciclesonide), Arnuity Ellipta (fluticasone furoate), Asmanex
More informationDiagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma
Diagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma Magnitude of Asthma - India Delhi Childhood asthma: 10.9% Adults: 8% Other Cities 3 to 18% Chhabra SK et al Ann Allergy Asthma
More informationSafety of β2-agonists in asthma
Safety of β2-agonists in asthma Sanjeeva Dissanayake IPAC-RS/UF Orlando Inhalation Conference March 20, 2014 Overview Origin of concerns Mechanistic hypotheses Large scale clinical datasets Interpretation
More informationbenralizumab (Fasenra )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationAsthma Hetereogeneity, Phenotypes and Endotypes Choosing the Right Biologic for your Patient
Asthma Hetereogeneity, Phenotypes and Endotypes Choosing the Right Biologic for your Patient Mario Castro MD, MPH Asthma & Airway Translational Research Unit Washington University School of Medicine St.
More informationAerospan (flunisolide)
STRENGTH DOSAGE FORM ROUTE GPID 80mcg/actuation HFA aerosol inhaler w/ Inhaled 35718 8.9 g/canister adapter MANUFACTURER Meda Pharmaceuticals INDICATION Aerospan Inhalation Aerosol is indicated for the
More informationAsthma Upate 2018: What s New Since the 2007 Asthma Guidelines of NAEPP?
10:50-11:50am Asthma Update 2018: What s New Since the 2007 National Asthma Guidelines? SPEAKER Christopher H. Fanta, MD Disclosures The following relationships exist related to this presentation: Christopher
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Nucala) Reference Number: CP.PHAR.200 Effective Date: 04.01.16 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important Reminder at
More informationNew Drug Evaluation: mepolizumab for injection
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationSevere Asthma(s): Can THEY be prevented or reversed?
Severe Asthma(s): Can THEY be prevented or reversed? Sally Wenzel, MD Professor of Medicine UPMC Chair in Translational Airway Biology Disclosures Sally Wenzel, M.D. Grant/Research Support: Boehringer-Ingelheim,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Fasenra) Reference Number: CP.PHAR.## Effective Date: 01.16.18 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationKey features and changes to these four components of asthma care include:
Guidelines for the Diagnosis and Management of Asthma in Adults Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions regarding
More informationAsthma in Pregnancy. Asthma. Chronic Airway Inflammation. Objective Measures of Airflow. Peak exp. flow rate (PEFR)
Chronic Airway Inflammation Asthma in Pregnancy Robin Field, MD Maternal Fetal Medicine Kaiser Permanente San Francisco Asthma Chronic airway inflammation increased airway responsiveness to a variety of
More informationBreathe Easy: Ensuring Care Coordination for Patients with Asthma
Breathe Easy: Ensuring Care Coordination for Patients with Asthma Target Audience: Pharmacists ACPE#: 0202-0000-18-051-L01-P Activity Type: Application-based Disclosures Lauren E. Bode none Dennis Williams
More informationExhaled Nitric Oxide: An Adjunctive Tool in the Diagnosis and Management of Asthma
Exhaled Nitric Oxide: An Adjunctive Tool in the Diagnosis and Management of Asthma Jason Debley, MD, MPH Assistant Professor, Pediatrics Division of Pulmonary Medicine University of Washington School of
More information#1 cause of school absenteeism in children 13 million missed days annually
Asthma Update 2013 Jennifer W. McCallister, MD, FACP, FCCP Associate Professor Pulmonary & Critical Care Medicine The Ohio State University Wexner Medical Center Disclosures None 2 Objectives Review burden
More informationBreakfast Session Prof Neil Barnes Professor of Respiratory Medicine London Chest Hospital & The Royal London Hospital United Kingdom
Breakfast Session Prof Neil Barnes Professor of Respiratory Medicine London Chest Hospital & The Royal London Hospital United Kingdom 2 BEYOND SYMPTOMS ADDRESSING FUTURE RISK IN ASTHMA South GP CME 2013,
More informationClinical Policy: Dupilumab (Dupixent) Reference Number: ERX.SPA.49 Effective Date:
Clinical Policy: (Dupixent) Reference Number: ERX.SPA.49 Effective Date: 06.01.17 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationNG80. Asthma: diagnosis, monitoring and chronic asthma management (NG80)
Asthma: diagnosis, monitoring and chronic asthma management (NG80) NG80 NICE has checked the use of its content in this product and the sponsor has had no influence on the content of this booklet. NICE
More informationreslizumab (Cinqair )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationClinical trial efficacy: What does it really tell you?
Clinical trial efficacy: What does it really tell you? Joseph Spahn, MD Denver, Colo The primary goal of most clinical trials is an evaluation of the efficacy of the drug being evaluated. Therefore, it
More informationPreschool Asthma What you need to know in 10 minutes
Preschool Asthma What you need to know in 10 minutes Alan Kaplan MD CCFP(EM) FCFP Family Physician Airways Group of Canada Respiratory Medicine section CFPC Faculty/Presenter Disclosure Faculty: Alan Kaplan
More informationRecurrent Wheezing in Preschool Children. William Sheehan, MD Associate Professor of Pediatrics Division of Allergy and Immunology
Recurrent Wheezing in Preschool Children William Sheehan, MD Associate Professor of Pediatrics Division of Allergy and Immunology Disclosure I have nothing to disclose related to this talk. Background
More informationAsthma: Classification, Management, Prevention and New Treatments
Asthma: Classification, Management, Prevention and New Treatments Cori Daines, MD, Professor Pediatric Pulmonary Medicine University of Arizona April 28, 2018 I have no relevant financial relationships
More informationDrug Prior Authorization Guideline NUCALA (mepolizumab)
Drug Prior Authorization Guideline MB9914 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes as shown below Restricted to Pulmonology, Allergy, and
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Interleukin (IL)-5 Antagonists: Mepolizumab and Reslizumab Table of Contents Coverage Policy... 1 General Background... 3 Coding/Billing Information... 5
More informationSevere Asthma & Exacerbations: Dawn of a New Era?
Severe Asthma & Exacerbations: Dawn of a New Era? Christophe von Garnier Department of Pulmonary Medicine Syndromes, Phenotypes & Endotypes Asthma Syndrome Variable symptoms, expiratory airflow limitation,
More informationTREAMENT OF RECURRENT VIRUS-INDUCED WHEEZING IN YOUNG CHILDREN. Dr Lại Lê Hưng Respiratory Department
TREAMENT OF RECURRENT VIRUS-INDUCED WHEEZING IN YOUNG CHILDREN Dr Lại Lê Hưng Respiratory Department Literature review current through: Feb 2013. This topic last updated: Aug 14, 2012 INTRODUCTION Wheezing
More informationDifficult Asthma Assessment: A systematic approach
Difficult Asthma Assessment: A systematic approach Dr Naghmeh Radhakrishna Respiratory, Sleep & Allergy Physician Allergy, Asthma & Clinical Immunology Service The Alfred Hospital Melbourne, Australia
More informationClinical Policy: Mepolizumab (Nucala) Reference Number: ERX.SPA.214 Effective Date:
Clinical Policy: (Nucala) Reference Number: ERX.SPA.214 Effective Date: 07.01.16 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationAPPENDIX 1 Printable point-of-care tables Asthma Action Plan Yellow Zone Formulation Table Region: Europe
APPENDIX 1 Printable point-of-care tables Asthma Action Plan Yellow Zone Formulation Table Region: Europe Instructions: Print on 8.5 x14 (216 x 279 mm) paper (Legal size) Medication in Green Zone Change
More informationThe Acute & Maintenance Treatment of Asthma via Aerosolized Medications
The Acute & Maintenance Treatment of Asthma via Aerosolized Medications Douglas S. Gardenhire, EdD, RRT-NPS, FAARC Associate Professor and Chairman Department of Respiratory Therapy Objectives Define Asthma.
More informationThe FDA Critical Path Initiative
The FDA Critical Path Initiative Clinical Considerations for Demonstration of Dose-response for Inhaled Corticosteroids - Exhaled Nitric Oxide Model Badrul A. Chowdhury, MD, PhD Director Division of Pulmonary
More information7/7/2015. Somboon Chansakulporn, MD. History of variable respiratory symptoms. 1. Documented excessive variability in PFT ( 1 test)
Definition of Asthma GINA 2010: Chronic inflammatory disorder of the airways Airway hyper-responsiveness Recurrent wheezing, breathlessness, chest tightness, coughing Variable, reversible airflow obstruction
More informationClinical Policy: Omalizumab (Xolair) Reference Number: ERX.SPA.141 Effective Date: Last Review Date: 08.17
Clinical Policy: (Xolair) Reference Number: ERX.SPA.141 Effective Date: 03.01.14 Last Review Date: 08.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationChallenges in Meeting International Requirements for Clinical Bioequivalence of Inhaled Drug Products
Challenges in Meeting International Requirements for Clinical Bioequivalence of Inhaled Drug Products Tushar Shah, M.D. Sr. VP, Global Respiratory Research and Development TEVA Pharmaceuticals 1 Presentation
More informationSponsor. Generic drug name. Trial indication(s) Protocol number. Protocol title. Clinical trial phase. Study Start/End Dates.
Sponsor Novartis Generic drug name Fluticasone propionate Trial indication(s) Moderate-severe bronchial asthma Protocol number CQAE397A2202 Protocol title A randomized open label study to assess the utility
More informationFASENRA (benralizumab)
FASENRA (benralizumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationStep up if needed (first, check adherence, environmental control and comorbid conditions) Patients ASSESS CONTROL. Step down if possible
12/9/212 Pharmacogenomics Treating the Individual Asthma Patient Elliot Israel, M.D. Professor of Medicine Harvard Medical School Brigham & Women s Hospital Partners Asthma Center Too much of a good thing?
More informationBiologics in Asthma: Present and Future
Biologics in Asthma: Present and Future Flavia Hoyte, MD Associate Professor of Medicine Fellowship Training Program Director Division of Allergy and Immunology National Jewish Health and University of
More informationTraiter l asthme sévère par le phénotype. Dr. Alain Michils CUB-Hôpital Erasme
Traiter l asthme sévère par le phénotype Dr. Alain Michils CUB-Hôpital Erasme Darwin 25 mars 2017 Step 5 treatment (GINA 2016) STEP 5 STEP 4 PREFERRED CONTROLLER CHOICE STEP 1 STEP 2 Low dose ICS STEP
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Xolair (omalizumab) Page 1 of 15 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Xolair (omalizumab) Prime Therapeutics will review Prior Authorization requests.
More informationCurrent Asthma Therapy: Little Need to Phenotype. Phenotypes of Severe Asthma. Cellular Phenotypes 12/7/2012
Subbasement Membrane Thickness(µm) 12/7/212 Current Asthma Therapy: Little Need to Phenotype Phenotypes of Severe Asthma Most mild and to some degree moderate asthmatics respond well to currently available
More informationBiologicals in the management of bronchial asthma. Deepa Shrestha
Biologicals in the management of bronchial asthma Deepa Shrestha Overview of the seminar Burden of asthma and need of biologicals Immunology of asthma Possible targeted therapy Available biologicals used
More informationCLINICAL MEDICAL POLICY
CLINICAL MEDICAL POLICY Policy Name: Xolair (omalizumab) Policy Number: MP-051-MD-DE Responsible Department(s): Medical Management; Clinical Pharmacy Provider Notice Date: 10/01/2017 Original Effective
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 07/05/18 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:
CINQAIR (reslizumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationCurrent Asthma Management: Opportunities for a Nutrition-Based Intervention
Current Asthma Management: Opportunities for a Nutrition-Based Intervention Stanley J. Szefler, MD Approximately 22 million Americans, including 6 million children, have asthma. It is one of the most prevalent
More informationPersonalized medicine in childhood asthma. Dr Mariëlle Pijnenburg, Erasmus MC Sophia, Rotterdam, NL
Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS for your personal use only, as submitted by the author.
More informationAdjustment of Inhaled Controller Therapy of Asthma in the Yellow Zone, Based on the Inhaler Product Used in the Green Zone Age 16 Years and Older
Adjustment of Inhaled Controller Therapy of Asthma in the Yellow Zone, Based on the Inhaler Product Used in the Green Zone Age 16 Years and Older The Canadian Thoracic Society and other international asthma
More informationAsthma training. Mike Levin Division of Asthma and Allergy Red Cross Hospital
Asthma training Mike Levin Division of Asthma and Allergy Red Cross Hospital Introduction Physiology Diagnosis Severity Treatment Control Stage 3 of guidelines Acute asthma Drug delivery Conclusion Overview
More informationSEVERE ASTHMA - EVIDENCE TABLES APPENDIX 1
Section 2: Biomarkers Biomarkers to predict response to biologic therapies and macrolides Summary of randomized controlled trials Cut-offs Cut-off selection Study Design N Drug Predictive ability to identify
More informationAsthma - An update BTS Asthma Guidelines 2016
Asthma - An update BTS Asthma Guidelines 2016 Dr Ian Clifton Overview Diagnosis Supported self-management Non-pharmacological management Drugs / inhaled therapy Difficult asthma services Case discussions
More informationASTHMA IN THE PEDIATRIC POPULATION
ASTHMA IN THE PEDIATRIC POPULATION SEARCH Rotation 2 August 23, 2010 Objectives Define asthma as a chronic disease Discuss the morbidity of asthma in pediatrics Discuss a few things that a health center
More informationUsing Inhaled Corticosteroids as Needed for Asthma: giving patients relief or leaving them breathless?
Using Inhaled Corticosteroids as Needed for Asthma: giving patients relief or leaving them breathless? Lindsay Thomas, Pharm.D. PGY2 Ambulatory Care Resident Department of Pharmacotherapy and Pharmacy
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationInterventions to improve adherence to inhaled steroids for asthma. Respiratory department
Interventions to improve adherence to inhaled steroids for asthma Respiratory department Content Overview Research References Overview Asthma is a chronic breathing condition that affects more than 300
More informationClinical efficacy of montelukast in anti-inflammatory treatment of asthma and allergic rhinitis
Clinical efficacy of montelukast in anti-inflammatory treatment of asthma and allergic rhinitis Kim Hyun Hee, MD, PhD. Dept. of Pediatrics The Catholic University of Korea College of Medicine Achieving
More informationStudy designs and PD/Clinical endpoints to demonstrate therapeutic equivalence: European Views
IPAC-RS/University of Florida Study designs and PD/Clinical endpoints to demonstrate therapeutic equivalence: European Views 20 th March 2014 Dr. Alfredo García - Arieta Head of the Service of Generic
More informationClinical Policy: Mepolizumab (Nucala) Reference Number: ERX.SPA.214 Effective Date:
Clinical Policy: (Nucala) Reference Number: ERX.SPA.214 Effective Date: 07.01.16 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationTips on managing asthma in children
Tips on managing asthma in children Dr Ranjan Suri Consultant in Respiratory Paediatrics Bupa Cromwell Hospital Clinics: Friday (pm) Asthma in Children Making the diagnosis Patterns of childhood asthma
More information-agonist therapy could improve the lives of patients with uncontrolled persistent asthma compared with standard therapy alone.
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β 2 agonist: a randomised double-blind placebo-controlled
More informationProf Neil Barnes. Respiratory and General Medicine London Chest Hospital and The Royal London Hospital
Prof Neil Barnes Respiratory and General Medicine London Chest Hospital and The Royal London Hospital ASTHMA: WHEN EVERYTHING FAILS WHAT DO YOU DO? South GP CME 2013, Dunedin Saturday 17 th August 2013
More informationDifferent kinds of asthma, different kinds of therapies
Different kinds of asthma, different kinds of therapies Friday 10 th November 2017 XXXIII Congresso Sezione SIAAIC Toscana Professor Neil Barnes Medical Head Global Respiratory Franchise, GSK Brentford,
More informationPhenotypes of asthma; implications for treatment. Medical Grand Rounds Feb 2018 Jim Martin MD DSc
Phenotypes of asthma; implications for treatment Medical Grand Rounds Feb 2018 Jim Martin MD DSc No conflicts to declare Objectives To understand the varied clinical forms of asthma To understand the pathobiologic
More informationImproving Outcomes in the Management & Treatment of Asthma. April 21, Spring Managed Care Forum
Improving Outcomes in the Management & Treatment of Asthma April 21, 2016 2016 Spring Managed Care Forum David M. Mannino, M.D. Professor Department of Preventive Medicine and Environmental Health University
More informationAsthma Update A/Prof. John Abisheganaden. Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital
Asthma Update - 2013 A/Prof. John Abisheganaden Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital Asthma A complex syndrome Multifaceted disease Heterogeneous Genetic and
More informationUpdates in the Management of Asthma and COPD. Case 1
Updates in the Management of Asthma and COPD Soraya Azari, MD Associate Clinical Professor of Medicine Case 1 40yo F with a history of asthma, allergic rhinitis, nicotine dependence, and obesity comes
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Xolair (omalizumab) Page 1 of 15 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Xolair (omalizumab) Prime Therapeutics will review Prior Authorization requests.
More informationTaking Control of Asthma Through Proper Medication Selection and the Use of Asthma Action Plans Julie M. Koehler, Pharm.D., FCCP
Taking Control of Asthma Through Proper Medication Selection and the Use of Asthma Action Plans Julie M. Koehler, Pharm.D., FCCP Associate Dean for Clinical Education and External Affiliations & Professor
More informationImmunomodulators: Anti-IgE mab. Thomas B. Casale, MD Professor of Medicine Chief, Allergy/Immunology Creighton University Omaha, NE
Immunomodulators: Anti-IgE mab Thomas B. Casale, MD Professor of Medicine Chief, Allergy/Immunology Creighton University Omaha, NE Objectives To explain the rationale behind IgE blockade To discuss which
More information2/4/2019 STEROIDS: THE GOOD, THE BAD AND THE UGLY! CONFLICT OF INTEREST, DISCLOSURES AND CONFESSIONS OUTLINE MICHAEL ZACHARISEN, MD.
STEROIDS: THE GOOD, THE BAD AND THE UGLY! MICHAEL ZACHARISEN, MD. CONFLICT OF INTEREST, DISCLOSURES AND CONFESSIONS Conflict of interest: None Disclosures: I prescribe steroids and have for 31 years I
More information